Silver Book Fact

Lifespan of Medicare patients with sSAS who do not undergo treatment

Medicare patients with severe symptomatic aortic stenosis (sSAS) who do not undergo treatment have an average lifespan of 1.8 years.

Five-Year Clinical and Economic Outcomes Among Patients with Medically Managed Severe Aortic Stenosis: Results from a Medicare claims analysis. Circulation: Cardiovascular Quality and Outcomes. 2012; 5(5). http://circoutcomes.ahajournals.org/content/5/5/697

Reference

Title
Five-Year Clinical and Economic Outcomes Among Patients with Medically Managed Severe Aortic Stenosis: Results from a Medicare claims analysis.
Publication
Circulation: Cardiovascular Quality and Outcomes
Publication Date
2012
Volume & Issue
Volume 5, Issue 5
URL
Read Full Resource

Categories

  • Cost of Disease
  • Human Burden

Connected Facts

Related Facts

  • 1 and 6-month mortality rates without treatment for sSAS
    Waiting for treatment for severe symptomatic aortic stenosis (sSAS) can be deadly, with 1-month mortality at 3.7% and 6-month mortality at 11.6% (measured from the time intervention was recommended).  
  • Aortic valve disease costs
    Aortic valve disease (AVD) (symptomatic and asymptomatic) costs the U.S. $10.2 billion in direct costs each year.  
  • 2016 prevalence of aortic valve disease in America
    In 2016, as many as 5.8 million U.S. adults had aortic valve disease (AVD). Note: Alliance for Aging Research generated statistic, based on 2005 percentage prevalence estimates by Bach et al. 2007  
  • Survival rates for patients with sSAS without repair or replacement
     
  • Moderate or severe aortic valve disease is present in 4.2% to 10.7% of the population ages 65 and older.